Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization
- First Online:
- 147 Downloads
The impact of persistence and compliance with bisphosphonate therapy on health care costs and utilization was examined in women newly prescribed bisphosphonates. At 3 years, women who were persistent and compliant with bisphosphonate therapy had lower total costs compared with non-persistent and non-compliant women, after controlling for relevant risk factors.
The impact of persistence and compliance with bisphosphonate therapy on health care costs and utilization was examined in bisphosphonate-naïve women.
Two claims databases were used to identify women ≥45 years of age and who filled a new bisphosphonate prescription during 2000–2002. Persistence and compliance were evaluated over 3 years. Compliance was defined as a medication possession ratio (days of bisphosphonate supply/days of follow-up) ≥0.80; persistence was defined as no refill gaps ≥30 days. Multivariate models accounted for potential confounders.
This analysis included 32,944 women (mean age, 64 years) who filled a new prescription for daily or weekly alendronate (n = 26,581) or risedronate (n = 6,363). At 3 years, 37% of women were compliant and 21% of women were persistent. Unadjusted total mean health care costs were lower for the compliant vs. non-compliant and persistent vs. non-persistent cohorts. After adjusting for potential confounders, total health care costs were reduced by 8.9% for persistent patients (p < 0.001) and 3.5% for compliant patients (p = 0.014). Persistence decreased the likelihood of inpatient admission by 47%.
At 3 years, women who were persistent and compliant with bisphosphonate therapy had lower total costs compared with non-persistent and non-compliant women, after controlling for relevant risk factors.
KeywordsBisphosphonates Compliance Cost Osteoporosis Persistence
- 3.Office of the Surgeon General (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. U.S. Department of Health and Human Services, Rockville, MDGoogle Scholar
- 7.Papapoulos SE (2000) Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Ann Med Interne (Paris) 151:504–510Google Scholar
- 11.Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar
- 15.Lombas C, Hakim C, Zanchetta JR (2001) Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 16(Suppl 1):S529Google Scholar
- 32.Gibson TB, Mark TL, Axelsen K, et al. (2006) Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 12 Spec no.:SP11–19Google Scholar